Health Care · Pharmaceutical Preparations

TGTX TG THERAPEUTICS, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1001316130 filings
Russell 2000

TGTX at a glance

TG THERAPEUTICS, INC. (TGTX, SEC CIK 1001316) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as September 14, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), TG THERAPEUTICS, INC. (TGTX) reported revenue of $616.3 million (up 87.3% from FY2024) and net income of $447.2 million. Diluted EPS was $2.77.
  • As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding TG THERAPEUTICS, INC. (TGTX) shares worth $3.8 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Charney Laurence N on September 10, 2026 of 5,000 shares at $54.96 per share.
  • In the last 90 days, TGTX insiders reported 0 open-market purchases ($0) and 1 open-market sale ($275K) on Form 4, a net sale of $275K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$616.3M
+87.3% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$275K
13F holders
34 funds
$3.8B · −2 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Fully integrated biotech focused on novel treatments for B-cell diseases, principally commercializing BRIUMVI for relapsing multiple sclerosis (RMS)
  • New initiatives: Launched Next In MS™ awareness platform with Christina Applegate; initiated Phase 3 enrollment for subcutaneous ublituximab; dosed first patient with azer-cel CAR T therapy in Phase 1 for progressive MS
  • Strategic shift: Expansion of BRIUMVI commercialization into Europe via $140M upfront deal with Neuraxpharm; emphasis on dosing schedule simplification and subcutaneous formulation development
  • Notable metric: Completed $100M share repurchase, acquiring 3.5 million shares at $28.55 average; Phase 3 subcutaneous ublituximab trial over 75% enrolled as of Feb 2026
  • Unique fact: Presented six-year data from ULTIMATE I & II trials showing 89.9% patients free from confirmed disability progression and ARR of 0.012, indicating sustained long-term efficacy and safety

Risk Factors

  • Cybersecurity breach risk impacting drug candidate development and commercialization via failures in internal or third-party CROs, CMOs, or contractors
  • Management oversight of cybersecurity risks with Board receiving regular reports on material threats and IT security effectiveness
  • Vice President of IT responsible for cybersecurity risk management, holds multiple certifications, with 25+ years experience

Management Discussion & Analysis

  • No capital allocation details such as buybacks, dividends, or capex mentioned
  • Forward-looking statements include general caution on risks and uncertainties

AI summary of the TGTX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added AI risk: evolving EU AI Act and related rules could increase compliance costs and liability
  • Regulatory risk: OBBBA coverage changes and CMS payment pilots could reduce reimbursement for multiple sclerosis medicines
  • Operational risk: reliance on Samsung Biologics and FUJIFILM limits BRIUMVI supply resilience
  • Competitive risk: faster or more effective rival therapies could reduce BRIUMVI adoption
  • Financial risk: $750 million 2026 Term Loan matures March 18, 2031, secured by substantially all assets

Management Discussion & Analysis

  • Q3 revenue $259.9M, up $98.2M YoY from $161.7M
  • BRIUMVI U.S. product revenue $232.6M, up from $152.9M YoY, best-performing product line
  • Gross margin 84% versus BRIUMVI U.S. margin 87%; net income $55.5M versus $390.9M
  • Nine-month operating cash flow $66.6M versus $(44.4)M YoY; financing provided $291.2M from 2026 Term Loan
  • Cash, equivalents and investments $556.7M; liquidity expected to fund operations beyond twelve months
  • Near-term headwinds: rising clinical, manufacturing, commercialization and interest expenses; subcutaneous BRIUMVI data expected year-end 2026 or Q1 2027

AI summary of the TGTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers TG Therapeutics’ third-quarter and nine-month results through September 30, 2026
  • Exhibit 99.1 contains the financial results and management commentary investors should review

Item EX-99.1: Item EX-99.1

  • Q3 revenue $259.9M, up from $161.7M, driven by BRIUMVI U.S. revenue $232.6M, up approximately 52% year over year
  • Full-year 2026 revenue guidance raised to approximately $1B, with BRIUMVI U.S. guidance raised to $915–920M
Filed Aug 3, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $240.3M, up from $141.1M; BRIUMVI U.S. sales $227.7M, up approximately 64% year over year
  • 2026 guidance raised to approximately $950M global revenue and $890–905M BRIUMVI U.S. revenue

Item 2.02: Results of Operations and Financial Condition

  • Press release announces TG Therapeutics’ second-quarter and first-half 2026 operating results
  • Results cover the three and six months ended June 30, 2026
Filed Jun 12, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All six director nominees elected through 2027, with support ranging from 54.85% to 88.63% of votes cast
  • Sagar Lonial received the weakest director support, with 45.15% withheld votes

AI summaries of TGTX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TGTX

Don't miss the next TGTX filing

  • Alerts as it files. A push when TGTX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TGTX, by share count.
  • Ask anything. An AI agent that reads every TGTX filing and answers with sources.

TGTX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Charney Laurence NSellSep 10, 2026$54.96
Charney Laurence NGAug 7, 2026-
Charney Laurence NGAug 7, 2026-
Charney Laurence NGAug 6, 2026-
Charney Laurence NAJun 11, 2026-
Hoberman KennethAJun 11, 2026-
Lonial SagarAJun 11, 2026-
HUME DANIELAJun 11, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$329.0M$616.3M
Operating Income-$41.9M$123.3M
Net Income$12.7M$23.4M$447.2M
Op. Margin-12.7%20.0%
Net Margin-7.1%72.6%
Balance Sheet
Total Assets$329.6M$577.7M$1.1B
Equity-$222.4M$648.0M
ROE-10.5%69.0%
Per Share
EPS$0.09$0.15$2.77
Cash Flow
Operating CF--$40.5M-$24.8M
CapEx$0$45K$214K

Source: XBRL data in TG THERAPEUTICS, INC. (TGTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TGTX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TGTX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202634$3.84B
Q2 202636$3.78B
Q1 202634$2.13B
Q4 202530$1.90B
Q3 202530$2.20B
Q2 202528$2.24B
Q1 202527$1.55B
Q4 202421$1.03B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 240 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TGTX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 9, 2026Analysis
8-KNov 9, 2026Analysis-
4Sep 14, 2026--
4Aug 7, 2026--
10-QAug 5, 2026Analysis
8-KAug 3, 2026Analysis-
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
8-KJun 12, 2026Analysis-
8-KJun 3, 2026Analysis
8-KMay 27, 2026Analysis
8-KMay 6, 2026Analysis
10-QMay 6, 2026Analysis
SC 13GApr 29, 2026-
8-KMar 20, 2026--
10-KFeb 27, 2026Analysis
8-KFeb 26, 2026Analysis-
4Jan 29, 2026-
8-KJan 13, 2026-
4Jan 9, 2026-
4Jan 9, 2026-
4Nov 25, 2025-

Related Health Care companies

All Health Care →

TGTX SEC filings: frequently asked questions

Are TGTX insiders buying or selling?

In the last 90 days, TG THERAPEUTICS, INC. (TGTX) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $274,800 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TGTX stock?

As of September 30, 2026, the largest TG THERAPEUTICS, INC. (TGTX) holders among the 13F filers tracked by SignalX were BlackRock ($1.3 billion), State Street Corp ($473.5 million), Vanguard Portfolio Management LLC ($439.6 million), Vanguard Capital Management LLC ($349.0 million), Two Sigma Investments ($188.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TGTX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), TG THERAPEUTICS, INC. (TGTX) reported revenue of $616.3 million (up 87.3% from FY2024) and net income of $447.2 million. Diluted EPS was $2.77. The figures come from the XBRL data in the 10-K.

What are the main risks in TGTX's latest 10-K?

In the 10-K filed February 27, 2026, TG THERAPEUTICS, INC. (TGTX) flagged: Cybersecurity breach risk impacting drug candidate development and commercialization via failures in internal or third-party CROs, CMOs, or contractors. Management oversight of cybersecurity risks with Board receiving regular reports on material threats and IT security effectiveness. (AI summary of the Risk Factors section.)

What did TGTX report in its latest 8-K?

TG THERAPEUTICS, INC. (TGTX) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers TG Therapeutics’ third-quarter and nine-month results through September 30, 2026.

What are the latest TGTX SEC filings?

TG THERAPEUTICS, INC. (TGTX) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on September 14, 2026.

What is TGTX's SEC CIK number?

TG THERAPEUTICS, INC. (TGTX)'s SEC Central Index Key (CIK) is 1001316. EDGAR lists every TGTX filing under that number.

Ask anything about TGTX

The research agent reads TGTX's filings, financials, insider trades and 13F holders, then answers with sources.